RxDoctor Payments Data

Terri Agan

Nurse Practitioner · Seymour, INNPI 1659335974

Payments from drug & device makers

$4,539in general payments, 2019–2025

Across 279 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$859
  • Lilly USA, LLC$831
  • AstraZeneca$451
  • GSK$355
  • Novartis$302
  • Pfizer$231
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$401%
  • Food & beverage$4,43898%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,539 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$5,653
Medicare patients
124
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin119$117,969
EliquisApixaban103$108,442
TrulicityDulaglutide38$55,591
MounjaroTirzepatide43$49,715
FarxigaDapagliflozin Propanediol39$46,475
JanuviaSitagliptin Phosphate42$40,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$37,946
OzempicSemaglutide36$35,725
LinzessLinaclotide23$26,712
XareltoRivaroxaban23$25,442
MyrbetriqMirabegron11$8,231
GemtesaVibegron12$7,888
Atorvastatin Calcium466$3,250
Omeprazole336$3,240
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$226$117,969119 claims
PfizerEliquis$231$108,442103 claims
Lilly USA, LLCTrulicity, Mounjaro$831$105,30581 claims
AstraZenecaFarxiga$451$46,47539 claims
MerckJanuvia$86$40,39942 claims
GSKTrelegy Ellipta$355$37,94629 claims
Novo NordiskOzempic$205$35,72536 claims
AbbVieLinzess, Synthroid$859$28,00358 claims
Astellas Pharma US IncMyrbetriq$13$8,23111 claims
Sumitomo Pharma America, Inc.Gemtesa$23$7,88812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Seymour

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →